anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Klebsiella pneumoniae (KP) is the second most prevalent Gram-negative bacterium causing bloodstream infections (BSIs). In recent years, the management of BSIs caused by KP has become increasingly complex due to the emergence of carbapenem-resistant Klebsiella pneumoniae (CRKP). Although numerous studies have explored the risk factors for the development of CRKP-BSIs, the mortality of patients with KP-BSIs, and the molecular epidemiological characteristics of CRKP, the variability in data across different populations, countries, and hospitals has led to inconsistent conclusions. In this single-center retrospective observational study, we utilized logistic regression analyses to identify independent risk factors for CRKP-BSIs and factors associated with mortality in KP-BSI patients. Furthermore, a risk factor-based prediction model was developed. CRKP isolates underwent whole-genome sequencing (WGS), followed by an evaluation of microbiological characteristics, including antimicrobial resistance and virulence genes, as well as epidemiological characteristics and phylogenetic analysis.
RESULTS: Our study included a total of 134 patients with KP-BSIs, comprising 50 individuals infected with CRKP and 84 with carbapenem-susceptible Klebsiella pneumoniae (CSKP). The independent risk factors for CRKP-BSIs were identified as gastric catheterization (OR = 9.143; CI = 1.357-61.618; P = 0.023), prior ICU hospitalization (OR = 4.642; CI = 1.312-16.422; P = 0.017), and detection of CRKP in non-blood sites (OR = 8.112; CI = 2.130-30.894; P = 0.002). Multivariate analysis revealed that microbiologic eradication after 6 days (OR = 3.569; CI = 1.119-11.387; P = 0.032), high Pitt bacteremia score (OR = 1.609; CI = 1.226-2.111; P = 0.001), and inappropriate empirical treatment after BSIs (OR = 6.756; CI = 1.922-23.753; P = 0.003) were independent risk factors for the 28-day mortality in KP-BSIs. The prediction model confirmed that microbiologic eradication after 6.5 days and a Pitt bacteremia score of 4.5 or higher were significant predictors of the 28-day mortality. Bioinformatics analysis identified ST11 as the predominant CRKP sequence type, with blaKPC-2 as the most prevalent gene variant. CRKP stains carried multiple plasmid-mediated resistance genes along with some virulence genes. Phylogenetic analysis indicated the presence of nosocomial transmission of ST11 CRKP within the ICU.
CONCLUSIONS: The analysis of risk factors for developing CRKP-BSIs and the association between KP-BSIs and 28-day mortality, along with the development of a risk factor-based prediction model and the characterization of CRKP strains, enhances clinicians' understanding of the pathogens responsible for BSIs. This understanding may help in the timely administration of antibiotic therapy for patients with suspected KP-BSIs, potentially improving outcomes.
Binocular double vision in strabismus is marked by diplopia (seeing the same object in two different directions) and visual confusion (seeing two different objects in the same direction). In strabismus with full visual field, the diplopia coexists with visual confusion across most of the binocular field. With visual field loss, or with use of partial prism segments for field expansion, the two phenomena may be separable. This separability is the focus of this review and offers new insights into binocular function. We show that confusion is necessary but is not sufficient for field expansion. Diplopia plays no role in field expansion but is necessary for clinical testing of strabismus, making such testing difficult in field loss conditions with confusion without diplopia. The roles of the three-dimensional structure of the real world and the dynamic of eye movements within that structure are considered as well. Suppression of one eye's partial view under binocular vision that develops in early-onset (childhood) strabismus is assumed to be a sensory adaption to diplopia. This assumption can be tested using the separation of diplopia and confusion.
Hypertension is a major complication following cardiac transplantation, with a prevalence of 93% at 5 years post-transplant. Post-cardiac transplant hypertension is due to multiple factors such as use of cyclosporine, chronic kidney disease, and denervation. Hypertension in this population is difficult to treat, and most patients require therapy with multiple antihypertensive agents in order to achieve adequate blood pressure control. Aliskiren, a direct renin inhibitor, is a novel antihypertensive agent with a unique mechanism of action and potent blood pressure-lowering effects. As such, aliskiren is an attractive treatment option for post-cardiac transplant hypertension. This study will characterize the pharmacokinetic drug-drug interaction profile, pharmacodynamics, and safety of aliskiren 75 mg daily (low-dose) and 150 mg daily, when given in combination with cyclosporine, in cardiac transplant patients.
Core temperature should be monitored under general anesthesia. Because patients are prone to hypothermia during surgery, besides, pediatric patients are more vulnerable in temperature control. Conventional core temperature is monitored at esophagus, rectum, nasopharynx. But some of them are invasive and impossible in sometimes. Recently developed 3M™ Bair Hugger™ skin temperature which is applied on temporal artery is correlated with core temperature measured by esophageal prove in several studies. Its mechanism is making zero heat flux on skin applied. But it also cannot apply in head or facial surgery. Other studies showed conventional skin temperature over carotid artery is also correlated with core temperature. The investigators hypothesized using 3M™ Bair Hugger™ on carotid artery could be alternative method measuring core temperature. The purpose of this study is comparing 2 methods of temperature monitoring in pediatrics. First, conventional core temperature measure by esophageal stethoscope. Second, 3M™ Bair Hugger™ applying on carotid artery.
This is a randomized control trial to compare the effects of core stabilization versus generalized antenatal exercises for lumbopelvic pain in pregnant women. Females meeting the inclusion and exclusion criteria will be divided into three groups by convenient sampling technique. A sample size of 48 females with 16 females in each group. Group A will be treated by core stability exercises and group B will be treated by generalized antenatal exercises and group C will receive basic antenatal education. Group A and B will have three treatment sessions per week for 4 weeks. Females will be evaluated at baseline and 2nd and 4th week . Females will be screened by Patricks faber test, piriformis /FAIR test, p4/posterior pelvic pain provocation test and assessed by visual analogue scale (VAS) and pregnant women quality of life questionnaire (QOL- GRAV).
The increasing rate of opioid related overdose mortality is well documented in the literature and approached 15 per 100,000 in 2017. Because of a growing epidemic in the US, the medical community is under scrutiny to curtail opioid prescription. However, this is weighed against surgical outcomes; importantly, postoperative pain has adverse effects on function, recovery and quality of life.

Regional anesthesia provides a non opioid based, pain control strategy. First, regional anesthesia decreases systemic adverse events including respiratory failure in abdominal surgery, decreases length of stay and improves rehabilitation in common orthopedic procedures such as total knee arthroplasty and shoulder arthroplasty. Second, the physiologic benefits of regional anesthesia are compelling including augmented micro and macrocirculation, maintenance of body temperature and decreased systemic stress response through chemical sympathectomy. Finally, regional anesthesia has been established as safe in the microvascular and anesthesia literature for pediatric, and adult patients.
This will be a Westernized diet will be consisting of high amounts of grains, potatoes, rice and imported meats from livestock animals (beef, pork and chicken). The Westernized diet will be high in carbohydrate (55-65 E%) and lower in fat (30-35 E%).
PURPOSE:To provide an oil-based composition composed of aclarubicin (hydrochloride), a saturated medium fatty acid, unsaturated medium fatty acid or unsaturated higher fatty acid, and an iodized oil or vegetable oil, capable of transferring the antitumor substance to the tumor organ in high efficiency and improving the remedying effect of the substance. CONSTITUTION:The objective oil-based composition is composed of (A) aclarubicin or aclarubicin hydrochloride, (B) saturated or unsaturated medium fatty acid (e.g. capric acid, caprylic acid, etc.) and/or unsaturated higher fatty acid (e.g. linoleic acid and (C) an iodized oil (e.g. iodized poppy oil fatty acid ethyl ester) and/or a vegetable oil (e.g. sesame oil). Since the component A can be dissolved easily in the components B and C, a high-concentration solution of antitumor substance can be prepared. The concentration of the component A in the composition is 1-100mg(titer)/1ml, and the amount of the component B is 30-200pts.wt. per 1pt.wt. of aclarubicin hydrochloride.
PURPOSE:To obtain a surfactant excellent in interfacial activity and safeness for skin when used for fragrant cosmetics such as shampoo, rinse, soap, etc., by using a trehalose-6-fatty ester expressed by specified formula as the surfactant. CONSTITUTION:This surfactant consists of a trehalose-6-fatty ester expressed by general structural formula (in formula, R is an 8-12C acyl group), which is obtd. by condensation of trehalose and a lower alkylester of fatty acid. The lower alkylester of fatty acid used is obtd. by introducing lower alkyl groups to natural fatty acids such as soy bean fatty acid, beef tallow, olive oil, palm oil, etc., by an usual method. Namely, the fatty ester is obtd. by using a method to produce normal alkyl esters of cane sugar.
Questions are pushed to patients multiple times per week for up to 90 days post-discharge. Questions are limited to those checking vital signs that indicate worsening of infection. Patient answers to RPM questions trigger High or Medium alerts, which trigger a response by members of the intervention care team. RPM alerts are screened by a nurse-staffed call center. Nurses determine whether emergency care is needed. If not, the call center alerts a multidisciplinary care team that is led by a certified registered nurse practitioner (CRNP). CRNPs, who operate in a palliative care role, have prescribing authority and can modify care plans. In addition to reacting to RPM triggers, team members (e.g., CRNP, social workers, nurses) meet with the patient in-person or virtually in the week after discharge and at least twice more in the next 90 days, conduct assessments and a pharmacy review, develop care plans, and discuss advance directives).
Patients will receive Auto-Monitoring text messages. The Auto-Monitoring tool that will be used is a function within Somnoware (Somnoware, Inc.) patient management platform, which is the national KP benchmarked platform for sleep management software. Fixed scheduled follow-up visits will be scheduled at 1-month (telephone encounter), 3-months (in-person or video encounter), and 1-year (in-person or video encounter). This sequence of follow-up visits reflects current real-world practice. Patients are eligible for additional visits when self-initiated. Sleep questionnaires will be delivered at 1, 3, and 6 months and at 1 year.
Primary sclerosing cholangitis (PSC) is an immune-mediated liver disease of unknown pathogenesis, with a high risk to develop cirrhosis and malignancies. Functional dysregulation of T cells and association with genetic polymorphisms in T cell-related genes were previously reported for PSC. Here, we genotyped a representative PSC cohort for several disease-associated risk loci and identified rs56258221 (BACH2/MIR4464) to correlate with not only the peripheral blood T cell immunophenotype but also the functional capacities of naive CD4+ T (CD4+ TN) cells in people with PSC. Mechanistically, rs56258221 leads to an increased expression of miR4464, in turn causing attenuated translation of BACH2, a major gatekeeper of T cell quiescence. Thereby, the fate of CD4+ TN is skewed toward polarization into pro-inflammatory subsets. Clinically, people with PSC carrying rs56258221 show signs of accelerated disease progression. The data presented here highlight the importance of assigning functional outcomes to disease-associated genetic polymorphisms as potential drivers of diseases.
PURPOSE:To provide a medicinal drug exhibiting high prophylactic effect against various infections microorganisms, by using a human colony stimulation factor as an active component. CONSTITUTION:The objective agent contains a human colony stimulation factor (abbreviated as CSF), preferably a neutrophilic colony stimulation factor as an active component, and has the following physical and chemical properties. Molecular weight, 19,000+ or -1,000 by sodiumm dodecylsulfate-polyacrylamide gel electro-phoresis; ultraviolet absorption, exhibits a peak at 280nm and a valley at 250nm; amino acid sequence, the amino acid sequence from the N- terminal to the 21st residue is shown by the formula. It has been supposed that the phagocytic and bactericidal action of leukocyte is dominant in the prophylactic function of the host at the initial stage of microbial infection, and accordingly, it is expected that the promotion of the proliferation, differentiation and aging of neutrocyte and macrophage are effective to promote the prophylactic capability of the host and to provide an effective remedy for infections diseases. Actually, the above agent exhibits high prophylactic effect against various micro-organisms (e.g. Candida).
NEW MATERIAL:A compound expressed by the formula (R is 1-5C alkyl; n is 4-22). EXAMPLE:14-Methyl-1-pentadecanol. USE:A carcinogenic preventive agent effective against not only ascitic cancer and leukemia but also solid cancer. PREPARATION:For example, a natural substance such as wool grease is subjected to saponifying reaction in the presence of an alkali. An alcohol and a fatty acid are separated from the resultant substance after completing the reaction to provide wool alcohol, which is then subjected to molecular distillation to afford a low-boiling fraction. Fractionation is further carried out by reverse phase column chromatography and the fraction having the third highest polarity is subsequently fractionated by normal phase column chromatography and finally fractionated by high-performance liquid chromatography, etc., to afford the compound expressed by the formula.
Patients were given consolidation therapy for 8 cycles (1 cycle = 21 days) with the combination bortezomib, dexamethasone and lenalidomide. Patients received each cycle: the standard dose of bortezomib (1.3 mg/m2) on days 1, 4, 8 and 11; fixed dose of lenalidomide at 15 mg orally on days 1-14; and 3 days of dexamethasone at 40 mg total dose per day given on days 1, 8 and 15. Aspirin 325 mg/day orally on days 1-21 of each cycle was required unless the patient was treated with alternate prophylaxis of either low molecular weight heparin or coumadin.
Meningomyelocele is a common congenital condition and its reconstruction poses a challenge for surgeons. The dorsal intercostal artery (DICA) flap offers a one-stage tension-free closure with adequate results. This study, spanning from January 2019 to September 2022, analyses the outcome of nine DICA flaps for meningomyelocele reconstruction, where the average size of the DICA flap was 6.8 x 4.6 cm for an average defect of 6.33 x 4 cm. Notably, no post-operative blood transfusion was required, nor any complications occurred except for one patient's septic shock-related death. Two had post-operative cerebrospinal fluid (CSF) leak, repaired primarily with one requiring VP shunt. Based on our experience, the DICA flap, with its consistent anatomy, is a reliable option for the reconstruction of meningomyelocele defects.
Serious adverse reactions of myelitis and radiculitis have been reported in patients treated with QALSODY. Six patients treated with QALSODY experienced myelitis or radiculitis in the clinical studies. Two patients discontinued treatment with QALSODY and required symptomatic management with full resolution of symptoms. In the remaining 4 patients, symptoms resolved without discontinuation of QALSODY. If symptoms consistent with myelitis or radiculitis develop, diagnostic workup and treatment should be initiated according to the standard of care. Management may require interruption or discontinuation of QALSODY.
After 1 week of pre-cessation nicotine patch treatment (21 mg/24 h patches), participants will receive moclobemide (400 mg/day in 2 divided doses) for 11 weeks, ending 10 weeks after the target quit date. Nicotine patch treatment will continue at 21 mg/24 h for an additional week prior to the quit date, and then for 6 weeks after the quit date, followed by 14 mg/24 h for 2 weeks and 7 mg/24 h for 2 weeks. All treatment will terminate 10 weeks after the quit date.
Beginning between day 100-110, patients receive lenalidomide PO once daily. Treatment continues in the absence of disease progression or unacceptable toxicity.
Subjects between birth to \<18 years will be dosed on a body weight tiered regimen. Subjects ≥35kg will receive 10mg twice daily(BID) for 7 days followed by 5mg BID thereafter;\<35kg to 25kg will receive 8mg BID for 7 days followed by 4mg BID thereafter;\<25 to 18kg will receive 6mg BID for 7 days and then 3mg BID thereafter;\<18 to 12kg will receive 4mg BID for 7 days and then 2mg BID thereafter;\<12 to 9kg will receive 3mg BID for 7 days and then 1.5mg BID thereafter;\< 9kg to 6kg will receive 2 mg BID for 7 days and 1mg BID thereafter;\<6kg to 5kg will receive 1mg BID for 7 days and 0.5mg BID thereafter;\<5kg to 4kg will receive 0.6mg twice daily for 7 days and 0.3mg BID thereafter;PK cohort neonates ≥ 2.6kg will receive 0.1mg BID. Dose will be adjusted as determined by PK measurements (ie, to 0.2mg BID, 0.1mg daily or dose will stay the same).For the post PK cohort Neonates ˂4kg to 2.6kg, if confirmed by PK sub analysis,subjects will receive 0.2mg BID for 7 days and 0.1mg BID thereafter.
The treatment device includes an extraction mechanism, configured to extract a tissue sample from a patient or a tumor, coupled to a lysis mechanism. The lysis mechanism is configured to induce lysis of the tissue sample into a lysed tissue sample. The treatment device also includes an administration mechanism that is coupled to both the extraction mechanism and the lysis mechanism. Further included with the treatment device is an additive mechanism configured to add an additive solution to the lysed tissue sample before the lysed tissue sample is administered to the patient. Furthermore, the invention also provided a method for treating a cancer. The method includes the steps of extracting a tissue sample from a patient or a tumor into a chamber of a treatment device. Lysing the tissue sample into an laysed tissue sample within the chamber of the treatment device and administering the lysed tissue sample directly from the treatment device into the patient.
Monolayer protected nanoclusters (MPCs) are described herein. The MPCs contain a cluster of atoms or molecules (e.g. core) having bound thereto a plurality of ligands (e.g., monolayer). The ligands can be bound covalently or semi-covalently bound to the cluster. The ligands are generally in the form of a monolayer or mixed monolayer. The monolayer or mixed monolayer contains a plurality of ligands. In one embodiment, the monolayer and/or mixed monolayer contains 1,4-dithiolate ligands. The MPCs described herein exhibit improved quantum efficiency allowing for single cluster emissions to be measured. Moreover, some embodiments of the MPCs described herein exhibit enhanced redox activity, including the ability to transfer a plurality of electrons, i.e., up to about 19 or up to about 30 electrons under controlled conditions, while displaying improved overall chemical stability. Such behavior can be utilized in catalysis and nanoelectronics applications.
FIELD: medicine, stomatology, homeopathy. SUBSTANCE: composition for mouth cavity care comprising biologically active substances and special additives involves additionally homeopathic preparations taken in dilutions C6-C799 as preliminary prepared the potentiated, structurized solution taken in the definite quantitative ratio. The composition can be prepared as dental paste, gel, balsam, elixir, rinsing agent. The composition shows remineralizing, anti-inflammatory, trophic, adaptogenic and antioxidant effects. EFFECT: valuable medicinal properties of composition. 2 cl
A short-term sustained drug eluting coating for implantable medical devices is disclosed. The coating comprises a biocompatible matrix and at least one pharmacologically or biologically active agent and releases substantially one of all of its payloads within four to six weeks post-implantation. When a combination of pharmacological agents are incorporated in the disclosed sustained drug eluting matrix of a drug/device combination, at least one agent is preferred to substantially release in a short duration. Medical devices benefiting from such a desired sustained drug eluting coating include drug eluting cardiovascular, peripheral, and neurovascular stents, abdominal aortic aneurysm (AAA) prosthesis, anastomosis shunt, arterial/venous (AV) shunts etc. One embodiment of the invention is a sustained release coating or depot on or in a stent that releases substantially all of it payload for ischemic myocardial injury after a heart attack. The coating may be formed from biocompatible stable and absorbable polymers of natural and synthetic origins. Useful pharmacological agents for inhibiting vascular neointimal growth post-angioplasty that leads to restenosis include macrolide polyenes such as a rapamycin and all its derivatives and analogs; paclitaxel and all derivatives and analogs. Useful agents for other vascular conditions such as vulnerable plaques may comprise anti-inflammatory, anti-proliferative agents, and matrix metalloprotease (MMP) inhibitors.
This group will receive an 8 week course on mental health knowledge. The series has been designed as an eight-week program for youth ages 11-15 that uses games, short films, discussion questions, and exercises to engage with mental health and faith topics.
Bronchopulmonary dysplasia (BPD) is a common chronic lung disease in infants and the most frequent adverse outcome of premature birth, despite major efforts to minimize injury. It is thought to result from aberrant repair response triggered by either prenatal or recurrent postnatal injury to the lungs during development. Intrauterine inflammation is an important risk factor for prenatal lung injury, which is also increasingly linked to BPD. However, the specific mechanisms remain unclear. This review summarizes clinical and animal research linking intrauterine inflammation to BPD. We assess how intrauterine inflammation affects lung alveolarization and vascular development. In addition, we discuss prenatal therapeutic strategies targeting intrauterine inflammation to prevent or treat BPD.
Vaccine comprises toxoids of clostridium perfringens types A, B and D, Cl. oedematiens and Cl. septicum, a sorbent and a solvent. The antigenic activity of the 5 toxois is 2-100, 2-100, 1-80, 1-80 and 2-100 units/ml., respectively. Vaccine is useful for the prophylaxis and treatment of clostridiosis in animals and poultry, esp. gas gangrene, malignant edema, endometritis, vaginitis, mastitis, miscarriage, bradzot of sheep, enterotoxemia etc. particularly in newborn and young animals. The vaccine is stable on prolonged storage.